reports
- Jonathan Moreland
ALLE ALLEGION PLC
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SHBI SHORE BANCSHARES INC.
RPD RAPID7 INC.
NWBI NORTHWEST BANCSHARES INC.
HOO HERBALIFE NUTRITION LTD.
CALX CALIX NETWORKS
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
AP AMPCO-PITTSBURGH
GBLI GLOBAL INDEMNITY PLC
MSBI MIDLAND STATES BANCORP
INSE INSPIRED ENTERTAINMENT
WMG WARNER MUSIC GROUP CORP.
PMTS CPI CARD GROUP
BHC BAUSCH HEALTH COMPANIES INC.
VRCA VERRICA PHARMACEUTICALS
ESTC ELASTIC N.V.
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
TBTC INC.
VLA TABLE TRAC INC.
ONEW ARBOR METALS
ABCL ONEWATER MARINE
ALIT ABCELLERA BIOLOGICS
BMEA ALIGHT
PBBK INC. / DELAWARE
NRDY BIOMEA FUSION
OWL INC.
ENOV PB BANKSHARES
QDEL INC.
J NERDY INC.
MAIA BLUE OWL CAPITAL INC
SMRT ENOVIS CORPORATION
FISV QUIDEL CORP
PODC JACOBS SOLUTIONS INC.
GAM MAIA BIOTECHNOLOGY INC
NUTX SMARTRENT INC
BAER FISERV
TENX INC.
SGI COURTSIDE GROUP INC.
AFCG GENERAL DE ALQUILER DE MAQUINARIA
DSM NUTEX HEALTH INC
XELB WILDFIRE NEW PUBCO
ANNX INC.
KTTA TENAX THERAPEUTICS INC.
SOMNIGROUP INTERNATIONAL INC.
AFC GAMMA
INC.
DREYFUS STRATEGIC MUNICIPAL BOND FUND
INC.
XCEL BRANDS INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
PASITHEA THERAPEUTICS CORP
Comfort Systems Usa Inc: 1 director
A director at Comfort Systems Usa Inc sold 1,000 shares at 996.163USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Soleno Therapeutics Announces the Passing of Board Member William G. H...
Soleno Therapeutics Announces the Passing of Board Member William G. Harris REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno’s Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. “I have known Bill for many years, and always viewed him as a person of integrity, who exhibited pragmatism and a...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
POST POST HOLDINGS INC.
NWBI NORTHWEST BANCSHARES INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GLP GLOBAL PARTNERS LP
CALX CALIX NETWORKS
GAM GENERAL AMERICAN INVESTORS CO. INC.
PBI PITNEY BOWES INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
PED PEDEVCO CORP
VRCA VERRICA PHARMACEUTICALS
ONEW ONEWATER MARINE
BBWI BATH & BODY WORKS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
QDEL QUIDEL CORP
J JACOBS SOLUTIONS INC.
EBC EASTERN BANKSHARES INC
SMRT SMARTRENT INC
GTE GRAN TIERRA ENERGY INC.
MNR MACH NATURAL RESOURCES LP
RMI RIVERNORTH OPPOR MUN INC FD INC
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Health...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A and replay of the presentation will be available in the Investors section on the Company’s we...
Aptevo Therapeutics Inc: 1 director
A director at Aptevo Therapeutics Inc bought 13,513 shares at 1.490USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Shar...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno’s common stock. “These actions demonstrate our confidence in our commer...
Calix Inc: 2 directors
Two Directors at Calix Inc sold/sold after exercising options 470,000 shares at between 64.094USD and 65.337USD. The significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and P...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 wa...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VIAV VIAVI SOLUTIONS INC
ROG ROGERS CORPORATION
PBYI PUMA BIOTECHNOLOGY INC.
OMCL OMNICELL INC.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GPRK GEOPARK
FORM FORMFACTOR INC.
CALX CALIX NETWORKS
AME AMETEK INC.
AVNW AVIAT NETWORKS
EFR ENERGY FUELS
CAH CARDINAL HEALTH INC.
CMCO COLUMBUS MCKINNON CORPORATION
ORN ORION GROUP HOLDINGS
CHRW C.H. ROBINSON WORLDWIDE INC.
JBSS JOHN B. SANFILIPPO & SON INC.
LAUR LAUREATE EDUCATION INC. CLASS A
OSW ONESPAWORLD HOLDINGS (A)
FOX FOX CORPORATION CLASS B
AEYE AUDIOEYE INC
REEMF RARE ELEMENT RESOURCES
GCI GANNETT CO. INC.
CMPR CIMPRESS PLC
TT TRANE TECHNOLOGIES PLC
SOPH SOPHIA GENETICS SA
ROIV ROIVANT SCIENCES LTD
MCW MISTER CAR WASH INC
PPTA PERPETUA RESOURCES CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
FTAI FORTRESS TRANSN & INFRAS INVS LLC
NAMS NEWAMSTERDAM PHARMA COMPANY B.V.
GPCR STRUCTURE THERAPEUTICS
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
FTK FLOTEK INDUSTRIES INC.
IDR IDAHO STRATEGIC RESOURCES INC
ESEA EUROSEAS LTD
CDTX CIDARA THERAPEUTICS INC.
PRM PERIMETER SOLUTIONS INC
MAZE MAZE THERAPEUTICS INC
FRGE FORGE GLOBAL HLDGS INC
LTBR LIGHTBRIDGE CORP
GSAT GLOBALSTAR INC.
Soleno Therapeutics to Participate in Upcoming November Conferences
Soleno Therapeutics to Participate in Upcoming November Conferences REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November: Guggenheim Securities Healthcare Innovation ConferencePresentation Date: Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format: Fireside ChatWebcast: Stifel 2025 Healthcare ConferencePresentation Date: Wednesday, November 1...
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on ...
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn ...
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors Appointment adds three decades of financial and operational leadership to Soleno’s Board REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board n...
Soleno Therapeutics to Participate in Upcoming September Conferences
Soleno Therapeutics to Participate in Upcoming September Conferences REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September: Cantor Global Healthcare ConferencePresentation Date: Wednesday, September 3, 2025 at 1:00 PM ETPresentation Format: Fireside ChatWebcast: Wells Fargo Healthcare ConferencePresentation Date: Thursday, September 4, 2025 at 1:30 ...
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and...
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering ...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an ad...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject ...
Soleno Therapeutics Announces Preliminary Financial and Operational Re...
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between $31.0 million and $33.0 million....
Soleno Therapeutics Inc: 1 director
A director at Soleno Therapeutics Inc sold 3,830 shares at 82.760USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.